Table 1.
Prostate cancer disparities metrics
| End point | Group and metric | |||
|---|---|---|---|---|
| Autopsy prevalence (%) by decade of age | Asian Ancestry | European Ancestry | African Ancestry | References |
| 20–29 | 0.0 | 0.5 | 1.6 | Rebbeck and Haas 2014 |
| 30–39 | 4.0 | 8.4 | 35.5 | |
| 40–49 | 6.3 | 15.0 | 24.7 | |
| 50–59 | 17.3 | 26.9 | 39.6 | |
| 60–69 | 17.7 | 33.3 | 56.7 | |
| 70–79 | 25.4 | 35.4 | NA | |
| 80–89 | 33.2 | 49.0 | NA | |
| 90+ | 50.0 | 91.1 | NA | |
| Screened-detected cancer prevalence, men with PSA >4.0 and abnormal DRE | Prevalence | Group | ||
| Ghana | 5.8 | Age 50–74 | Hsing et al. 2014 | |
| AA-St. Louis, MO | 5.4 | Age 40–79 | Smith et al. 1996 | |
| AA-Detroit, MI | 3.3 | Age 40–79 | Powell 2007 | |
| AA-Flint, MI | 3.0 | Age 40–79 | Cooney et al. 2001 | |
| AA-South Carolina | 2.2 | Age 40–79 | Weinrich et al. 1998 | |
| U.S. Caucasians | 1.6 | Age >50 | Richie et al. 1993 | |
| Incidence (age-adjusted per 100,000 men) | SEER-18 rate 2008–2012 | SEER-13 trend 2003–2012 | ||
| Asian/Pacific Islander | 74.0 | −4.6 | seer.cancer.gov | |
| Black | 214.5 | −3.9 | ||
| Hispanic | 114.7 | −4.7 | ||
| Non-Hispanic White | 133.4 | −4.7 | ||
| Relative biochemical nonfailure, White vs. Black | HR = 1.25 | 95% CI: 1.11–1.41 | Evans et al. 2008 | |
| Relative CaP-specific survival, White vs. Black | HR = 1.13 | 95% CI: 1.00–1.27 | Evans et al. 2008 | |
| Relative overall survival, White vs. Black | HR = 1.01 | 95% CI: 0.88–1.16 | Evans et al. 2008 | |
| Mortality (age-adjusted per 100,000 men | SEER-18 rate 2008–2012 | SEER-13 trend 2003–2012 | ||
| Asian/Pacific Islander | 9.4 | −3.4 | seer.cancer.gov | |
| Black | 46.3 | −4.0 | ||
| Hispanic | 17.8 | −2.7 | ||
| Non-Hispanic White | 19.9 | −3.4 | ||
NA, Not available; AA, African American; PSA, prostate-specific antigen; DRE, digital rectal examination.